Managing Hyperglycemia and Rash Associated With Alpelisib: Expert Consensus Recommendations Using the Delphi Technique

January 2024 in “ NPJ breast cancer ”

Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura M. Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobágyi, Benjamin H. Kaffenberger, Bernice Y. Kwong, Timothy Pluard, Ruta Rao, Lee S. Schwartzberg, Michael S. Broder

alpelisib phosphatidylinositol-3-kinase inhibitor hyperglycemia rash metformin HbA1c endocrinology consult nonsedating H1 antihistamines topical steroids PI3K inhibitor blood sugar antihistamines steroids

Studysummary This study, using modified Delphi panels, provided consensus recommendations for managing alpelisib-induced hyperglycemia and rash, advising prophylactic metformin starting for certain risk groups and the use of nonsedating H1 antihistamines and topical steroids for initial rash management.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on nature.com →

Discuss this study in the Community →